# Diabetes Research Hub — Monitor Review

**Run:** 2026-07-07 (automated) · **Previous review:** 2026-07-06
**Scope:** File-system status, clinical-trial deltas, PubMed alerts, gap analysis, web scan
**Rule:** Review-only run — no source files modified.

---

## Bottom Line

One genuinely significant external event: the FDA approved **orforglipron (Foundayo, Eli Lilly)** on 2026-07-01 — the first once-daily oral GLP-1 pill for type 2 diabetes with no food/water restrictions. This directly maps to a therapy the hub already tracks (15 mentions in this cycle's PubMed pull) and to ~6 active Lilly orforglipron Phase 3 trials in our snapshot. Everything else is incremental. All primary data files ran on schedule and are dated today.

---

## File System Status

All five key outputs are fresh (generated 2026-07-07 02:04–02:13). Nothing missing, nothing stale among primary data.

| File | Status | Modified |
|------|--------|----------|
| hub_monitor_report.md | OK | 2026-07-07 |
| clinical_trials_latest.json (845 trials) | OK | 2026-07-07 |
| pubmed_recent_latest.json (152 papers) | OK | 2026-07-07 |
| literature_gap_data.json | OK | 2026-07-07 |
| literature_gap_report.md | OK | 2026-07-07 |

hub_monitor.py flagged **791 result files older than 14 days**. [Certain] This is expected — the bulk are dated daily `clinical_trials_snapshot_*` and `agent_state.json.bak_*` archives, not stale live data. No action needed unless disk hygiene is a concern (see Recommended Actions).

Scan totals: 1,019 files tracked · 4 new · 31 modified · 0 removed.

---

## Clinical Trial Changes (2026-07-06 → 07)

6 new trials, 0 removed, 1 status change, **0 new results posted.**

**Status change:**
- **NCT07675161** — NOT_YET_RECRUITING → **RECRUITING** — MiniMed Fit Payload Wear Pediatric Study (device).

**New trials worth noting:**
- **NCT07684144 — Amgen, PHASE 3, MariTide (maridebart cafraglutide) extension** ("MARITIME-2-EXTENSION"). Obesity + T2D, n=950, completion 2028-03. Long-term efficacy/safety extension of Amgen's incretin program — the main non-Lilly/Novo Phase 3 obesity-diabetes competitor. Not yet recruiting.
- **NCT07683026 — NIDDK, PHASE 2, Golimumab vs placebo in Stage 1 T1D** (platform trial). Anti-TNF immunomodulation for early-stage T1D — aligns with the hub's autoimmunity/disease-modification tracking. Not yet recruiting.
- Three NA-phase behavioral/device studies (AI drug-consultation, mHealth exercise, blood-flow-restriction) — routine, low priority.

**Key-organization Phase 3 landscape (unchanged this cycle, tracked for context):**
- **Vertex** VX-880 / zimislecel — two Phase 3 **RECRUITING** (NCT06832410, NCT04786262); VX-264 Phase 1/2 active.
- **Lilly** baricitinib beta-cell preservation — two Phase 3 **RECRUITING** (NCT07222332, NCT07222137).
- **Lilly** orforglipron — multiple Phase 3 (master protocol NCT06993792, NCT07668336, NCT07613307).
- **Novo** CagriSema + weekly insulin icodec — several Phase 3 active/not-yet-recruiting.

Total Phase 3 in RECRUITING status across the dataset: **42.**

---

## PubMed Highlights

33 new papers, 36 dropped since yesterday (152 unique in the 30-day window; 16 domains queried).

**Cross-domain new papers (highest value — appear in ≥2 alert domains):**
- [42404798] Gut microbiome–liver–host metabolome axis and therapeutic response — *Biomarker × Microbiome × Multi-Omics* (three-domain — top pick).
- [42406681] Molecular/genetic/pharmacological advances in T2D 2015–2025 — *Biomarker × Microbiome × Epigenetics*.
- [42404804] 24-month CV outcomes: semaglutide vs empagliflozin — *GLP-1 × Biomarker*.
- [42403562] ML classification model for T2D remission — *T2D Remission × AI/ML*.
- [42404345] Risk-stratification tool, rapidly-progressive diabetic retinopathy — *AI/ML × Biomarker × Complications*.
- (3 more AI/ML-adjacent papers in the full snapshot.)

**Key-therapy hits this cycle:** orforglipron 5 papers · teplizumab 5 · retatrutide 5 · CagriSema 5 · dapagliflozin 5 · icodec 4 · baricitinib 3 · **zimislecel 0**.

[Likely] The zimislecel zero is a keyword miss, not genuine absence — same finding as the last two reviews. The alert query does not include the "VX-880" alias while Vertex runs two Phase 3 trials under that name. This is a recurring, still-unfixed gap.

---

## Gap Analysis Summary

30 domains, 435 pairs. Top 5 under-researched intersections (all gap score 100.0, opportunity HIGH):

| Rank | Intersection | Joint Pubs | Expected |
|------|--------------|-----------|----------|
| 1 | Beta Cell Regen × Health Equity | 0 | 1,698 |
| 2 | Insulin Resistance × Islet Transplant | 1 | 2,221 |
| 3 | Insulin Resistance × Closed Loop / AP | 3 | 6,134 |
| 4 | Islet Transplant × GWAS / Polygenic | 0 | 1,146 |
| 5 | Islet Transplant × Personalized Nutrition | 0 | 403 |

**Tier-1 alignment:** Rank 1 (Beta Cell Regen × **Health Equity**) and several lower-ranked Islet-Transplant × **Drug Repurposing** / **Health Equity** pairs map onto Tier-1 contribution areas from RESEARCH_DOCTRINE.md. Islet Transplant (248 pubs) and the small mechanistic domains (Glucokinase 852, Drug Repurposing 604, LADA 575) dominate the gap list because their low individual volume inflates every intersection — treat these as terminology-sensitive candidates, not confirmed white space.

Evidence level for all gap claims: **BRONZE** — single computational source (PubMed count heuristics), requires combined-term verification before acting.

---

## Breaking News (web scan, last 7 days)

- **[Significant] FDA approved orforglipron (Foundayo, Eli Lilly) on 2026-07-01** — first once-daily oral GLP-1 pill for T2D, no food/water timing restriction. Confirmed via Lilly investor release and secondary coverage. Evidence: SILVER (two independent secondary sources; primary label pending).
- **[Watch] Amgen MariTide** biweekly-class data continuing to read out — consistent with the new MARITIME-2-EXTENSION Phase 3 above.
- Vertex Phase 3 stem-cell islet (zimislecel/VX-880) — positive data anticipated in 2026; **no new results posted in our snapshot** as of today.
- No new FDA diabetes actions beyond orforglipron this window. Routine ADA-2026 tech coverage skipped.

---

## Recommended Actions

1. **Tracker update (do first):** Record the **orforglipron / Foundayo FDA approval (2026-07-01)** in Diabetes_Research_Tracker.xlsx — it converts a tracked pipeline therapy to approved status.
2. **Fix the recurring keyword miss:** Add **"VX-880"** (and "zimislecel") aliases to the zimislecel query in `baseline_pubmed_alerts.py`. Flagged in the last two reviews and still zero. One-line fix, removes a persistent blind spot on Vertex's Phase 3 program.
3. **Log new Phase 3 entrants:** Add **NCT07684144 (Amgen MariTide extension)** and **NCT07683026 (NIDDK golimumab Stage 1 T1D)** to trial tracking.
4. **Review cross-domain paper:** PMID 42404798 (microbiome–liver–metabolome axis) — three-domain hit, relevant to the Multi-Omics Tier-1 pipeline.
5. **Optional disk hygiene:** 791 files >14 days old are mostly `agent_state.json.bak_*` and daily snapshots. Consider archiving snapshots older than ~30 days to a subfolder to keep the monitor's stale-file flag meaningful.
6. **No re-runs needed:** All primary scripts (baseline_clinical_trials.py, baseline_pubmed_alerts.py, project1_literature_gap_analysis.py, hub_monitor.py) ran today. Gap analysis is current.

---
*Automated review — no source files modified. Trial/PubMed deltas are [Certain] (direct snapshot diffs). Gap classifications BRONZE. News items SILVER pending primary-source confirmation. Doctrine v1.0.*
